Bortezomib Ups Response, Survival in Multiple Myeloma

Share this article:
Bortezomib Ups Response, Survival in Multiple Myeloma
Bortezomib Ups Response, Survival in Multiple Myeloma

(HealthDay News) – For patients with newly diagnosed multiple myeloma (MM), induction treatment with a combination of bortezomib, doxorubicin, and dexamethasone (PAD) followed by bortezomib maintenance therapy improves complete response (CR), progression-free survival (PFS), and overall survival (OS) rates, according to a study published online July 16 in the Journal of Clinical Oncology.

Pieter Sonneveld, MD, PhD, of the Erasmus Medical Center in Rotterdam, Netherlands, and colleagues conducted an open-label, randomized Phase 3 trial involving 827 patients with newly diagnosed, symptomatic MM. Participants were randomized to receive induction therapy with vincristine, doxorubicin, and dexamethasone (VAD) or PAD, followed by high-dose melphalan and autologous stem-cell transplantation. VAD-treated patients received thalidomide as the maintenance treatment and PAD-treated patients received maintenance bortezomib.

Compared to VAD, the researchers found that PAD induction yielded statistically significant superior CR and near CR rates (31% vs. 15%). The CR rate was also significantly improved with bortezomib maintenance therapy (49% vs. 34%). Compared to those treated with VAD, patients treated with PAD had superior PFS after a median of 41 months (median 35 months vs. 28 months; hazard ratio, 0.75; P=0.002) and overall survival was superior in multivariate analysis (hazard ratio, 0.77; P=0.049). The benefits of bortezomib induction and maintenance therapy were greatest in high-risk patients with creatinine levels in excess of 2mg/dL and in those with deletion 17p13.

"This randomized multicenter trial in patients with MM who were eligible for high-dose therapy demonstrates that bortezomib during induction and maintenance treatment results in a better response, quality of response, PFS, and OS," the authors write.

The study was funded in part by Janssen-Cilag-Ortho Biotech. Several authors and the German Multicenter Myeloma Group disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text
Editorial

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs